ConductScience.org, home

Library / Trials

Cardiopulmonary Complications of Electronic Cigarettes

NCT07924007, Not applicable, Not yet recruiting, University of Alberta

Trial 10

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

FieldValueSource
TitleCardiopulmonary Complications of Electronic CigarettesClinicalTrials.gov
NCT numberNCT07924007ClinicalTrials.gov
StatusNot yet recruitingClinicalTrials.gov
PhasesNot applicableClinicalTrials.gov
Enrollment480 participants, estimatedClinicalTrials.gov
Lead sponsorUniversity of AlbertaClinicalTrials.gov
ConditionsElectronic Cigarette Use, Cannabis UseClinicalTrials.gov
InterventionsLower body positive and negative pressure, ExerciseClinicalTrials.gov
First posted2026-11-09ClinicalTrials.gov
Last updated2026-11-09ClinicalTrials.gov

Registered outcomes 9

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescriptionSource
PrimaryDiffusing capacity of carbon monoxide (DLCO)Time Frame: Days 2 and 3. Measurements will be taken during each stage of intervention, after a minimum of 2 minutes from the onset of each stage.
Diffusing capacity of carbon monoxide (DLCO) in selected exercise intensities, lower-body pressures, and body positions. DLCO is measured using the single-breath dual gas pulmonary diffusing capacity for nitric oxide and carbon monoxide technique.
ClinicalTrials.gov
PrimaryCapillary blood volume (Vc)Time Frame: Days 2 and 3. Measurements will be taken during each stage of intervention, after a minimum of 2 minutes from the onset of each stage.Capillary blood volume is a component of DLCO and is measured with the single-breath dual gas pulmonary diffusing capacity for nitric oxide and carbon monoxide technique.ClinicalTrials.gov
PrimaryMembrane diffusing capacity (Dm)Time Frame: Days 2 and 3. Measurements will be taken during each stage of intervention, after a minimum of 2 minutes from the onset of each stage.Membrane diffusing capacity is a component of DLCO and is measured with the single-breath dual gas pulmonary diffusing capacity for nitric oxide and carbon monoxide technique.ClinicalTrials.gov
SecondaryExercise capacityAverage peak VO2 recorded during the final 30seconds of the highest workload.Exercise capacity (VO2peak) will be measured using an incremental exercise test.ClinicalTrials.gov
SecondaryPhysical activity - Step CountMeasured for 7 days after visit 1Physical activity (number of steps per day) will be measured using an activity monitor.ClinicalTrials.gov
SecondaryPhysical activity - Moderate to VigorousMeasured for 7 days after visit 1Number of minutes spent doing moderate to vigorous physical activity will be measured using an activity monitor.ClinicalTrials.gov
SecondaryCardiac structure and functionTime Frame: Day 4. Measurements will be taken during each stage of intervention, after a minimum of 2 minutes from the onset of each stage.Right ventricular systolic pressure during each intervention.ClinicalTrials.gov
SecondaryBlood volumeTime Frame: Visit 5. Measurement will be taken through study completion, an average of 10 minutes after the intervention.Total blood volume estimated using the carbon monoxide rebreathe method.ClinicalTrials.gov
SecondaryPulmonary vascular volumesTime Frame: Visit 6. Measurement will be taken through study completion, an average of 30 minutes per scan.Chest computed tomorgraphy (CT) scanClinicalTrials.gov

Outcomes 0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured asSource

Results by group 0

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnitsSource

Participant flow 0

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits countedSource

Adverse events 0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

TypeEventOrgan systemGroupAffectedAt riskEventsSource

Adverse event totals 0

The totals the trial posted for each group.

TotalGroupAffectedAt riskSource

Papers 5

The papers the trial lists on ClinicalTrials.gov.

PMIDListed asSource
30509717BACKGROUNDPubMed
33180648BACKGROUNDPubMed
35065052BACKGROUNDPubMed
38990977BACKGROUNDPubMed
41485699BACKGROUNDPubMed

Grants 0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

ProjectTitlePrincipal investigatorsOrganizationFunderFiscal yearsSource

Trial comparisons 0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

ComparisonSource

Tests 0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

TestNamed asSource

Source 5

FieldValueSource
Releasetrials-2026-11-12-0.4.0ClinicalTrials.gov
Release manifest SHA-2560f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4ClinicalTrials.gov
Registry capture2026-11-12ClinicalTrials.gov
Results copy, AACT2026-03-23ClinicalTrials.gov
NIH clinical studies file2026-11-13ClinicalTrials.gov

The same record as JSON

Release trials-2026-11-12-0.4.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)